miRNA-based diagnostics are designed to identify primary tumors and differentiate between lung cancers.
Australia-based Genetic Technologies obtained exclusive distribution rights to Rosetta Genomics’ miRNA-based cancer tests—miRview™ mets, miRview™ squamous, and miRview™ meso—in Australia, New Zealand, and Singapore.
miRview mets is designed to accurately identify the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview squamous differentiates squamous from nonsquamous non-small-cell lung cancer. miRview meso uses miRNA specificity as biomarkers to differentiate mesothelioma from other lung carcinomas.
Rosetta’s deal with Genetic Technologies follows a September agreement with AXA Diagnostics for distribution of the same three tests in Italy.
